In our study, inhibition of PCBP4 decreased cisplatin resistance in head and neck cancer cells, which suggests that PCBP4 is a major component of cisplatin resistance and a new target for treatment of HNSCC, by enhancement of the effects of chemo-radiotherapy with cisplatin. The gene discussed is PCBP4; the disease is head and neck squamous cell carcinoma.